Advertisement CRi receives approval for patent application for spectral imaging - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

CRi receives approval for patent application for spectral imaging

Cambridge Research & Instrumentation has reported that the US Patent Office has issued a notice of allowance for their patent application for spectral imaging of deep tissue.

This method patent covers the use of multispectral imaging combined with spectral unmixing to greatly increase the signal-to-noise level of fluorophores in a living mammal. The unmixing of tissue autofluorescence is a critical component in achieving quantitative, highly sensitive results from fluorophores in vivo.

The methodology covered by this allowance broadly covers multispectral imaging hardware and algorithm-based approaches including the use of Cambridge Research & Instrumentation (CRi’s) patented liquid crystal tunable filter technology and image acquisition and data analysis software packages.

Peter Miller, vice president and chief science officer of CRi, said: “This patent allowance further strengthens our position in the area of in vivo imaging and further validates CRi’s approach to providing customers with effective imaging solutions.”